Advanced Search

 

Study ID Status Title Patient Level Data
MD7111396 Completed An extension study to protocol MD7108240: pazopanib eye drops in subjects with neovascular age-related macular degeneration
MEE103219 Completed A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219) Study Listed on ClinicalStudyDataRequest.com
MEE103226 Completed A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous anti-human interleukin-5 (mepolizumab, 750mg and 1500mg) in the treatment of Eosinophilic Oesophagitis in Adults Study Listed on ClinicalStudyDataRequest.com
MEK111054 Completed An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors or Lymphoma
MET111516 Completed An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111643 Completed A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer Study Listed on ClinicalStudyDataRequest.com
MET111644 Completed A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma Study Listed on ClinicalStudyDataRequest.com
MET111646 Completed A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Study Listed on ClinicalStudyDataRequest.com
MET111647 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111648 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MHE104317 Recruiting 104317: An Open-Label Compassionate Use access and Long-Term Access Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome 201956: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study
MKC101614 Completed A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 7.5 mg per day in patients with chronic obstructive pulmonary disease.
MKI102428 Completed A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD) Study Listed on ClinicalStudyDataRequest.com
MKI106209 Completed A randomised, double-blind, placebo-controlled parallel study to assess the safety, tolerability,pharmacodynamics and steady state pharmacokinetics of repeated doses of GW856553 in patients with COPD
MKN106762 Completed A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma
MMRV (208136) - Meta-analysis Completed Integrated Summary Output (ISO) on febrile convulsions
MOT107043 Completed A First-Time-in-Human Randomized Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of the Oral Motilin Receptor Agonist GSK962040, in Male and Female Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
MOT109681 Completed A randomized, double-blind, ascending dose trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, of repeat doses of motilin receptor agonist GSK962040 in male and female healthy volunteers Study Listed on ClinicalStudyDataRequest.com
MT400-108 Completed Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets Administered Two Hours Apart on Chromosomal Aberrations in Peripheral Blood Lymphocytes
MT400-301 Completed A Double-Blind Multicenter, Randomized, Placebo-Controlled Single dose study to evaluate the safety and efficacy of Trexima in the acute treatment of migrane headaches
MT400-302 Completed A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy opf Trexima in the Acute Treatment of Migraine Headaches
MT400-303 Completed An Open-Label, Repeat Dose Study Of The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months
NAA104606 Completed A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia
NAA105416 Completed Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole 400mg on Pharmacokinetics of SB-773812 20mg.
NAA105737 Completed A single blind, double dummy, placebo controlled, randomized, 2 period crossover study to assess the relative bioavailability of a 120mg tablet compared to two 60 mg SB-773812 tablets in healthy volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.